INTANGIBLE ASSETS, NET (Tables)

6 Months Ended

Jun. 30, 2016

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Schedule of intangible assets

The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of June 30, 2016 and December 31, 2015:

	June 30, 2016
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Remaining Amortization Period (yrs.)
Amortizing intangible assets:
OPERA® software patent	$	31,951	$	(5,492	)	$	26,459		13.25
Development costs of corporate website		91,743		(91,743	)		—		n/a
Approved hormone therapy drug candidate patents		954,817		(73,490	)		881,327		16.5
Hormone therapy drug candidate patents (pending)		903,694		—			903,694		n/a
Non-amortizing intangible assets:
Multiple trademarks for vitamins/supplements		172,349		—			172,349		indefinite
TOTAL	$	2,154,554	$	(170,725	)	$	1,983,829

	December 31, 2015
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Remaining Amortization Period (yrs.)
Amortizing intangible assets:
OPERA® software patent	$	31,951	$	(4,493	)	$	27,458		13.75
Development costs of corporate website		91,743		(91,743	)		—		n/a
Approved hormone therapy drug candidate patents		705,752		(49,845	)		655,907		17
Hormone therapy drug candidate patents (pending)		774,165		—			774,165		n/a
Non-amortizing intangible assets:
Multiple trademarks for vitamins/supplements		157,721		—			157,721		indefinite
TOTAL	$	1,761,332	$	(146,081	)	$	1,615,251

Schedule of estimated amortization expense

Estimated amortization expense for the next five years is as follows:

Year Ending December 31,	Estimated Amortization
2016 (6 months)	$	26,819
2017	$	53,638
2018	$	53,638
2019	$	53,638
2020	$	53,638